Table 1.
Pharmacokinetic parameters of Ro 44-3888 after oral administration of sibrafiban (2 mg twice daily) alone or in combination with ticlopidine (250 mg twice daily) and aspirin (80 mg twice daily) for 7 days. Parameters are derived from free plasma concentrations.
| Treatment | ||
|---|---|---|
| Sibrafiban | Sibrafiban+ticlopidine/aspirin | |
| Parameter | (n = 12) | (n = 11) |
| Cmax (ng ml−1) | 9.05±2.35 | 8.97±2.15 |
| tmax (h) | 5.4±2.6 | 5.5±3.0 |
| AUC(0,12 h) (ng ml−1 h) | 74±20 | 72±12 |
| CLss (l h−1) | 25.9±7.0 | 25.4±4.3 |
| Cssav (ng ml−1) | 6.1±1.6 | 6.0±1.0 |
| Urnary excretion* | 57.0±8.5 (n = 11) | 63.1±9.5 |
Values are expressed as mean±standard deviation of the mean.
Cmax: maximal plasma concentration (mean of the maximal values observed for each volunteer).
tmax: time of maximal plasma concentration.
AUC(0,12 h): area under the concentration-time curve from time 0 to 12 h.
CLss: apparent systemic clearance after oral administration at steady state.
Cssav: average steady state concentration.
*
as a percentage of the dose of RO 44-3888.